Cell-Penetrating Peptides and Cancer Drug Delivery

TAT Peptide

30+ years

Cell-penetrating peptides have been studied since the late 1980s, when researchers discovered that the HIV TAT protein could cross cell membranes and carry cargo inside.

Derakhshankhah & Jafari, Biomedicine & Pharmacotherapy, 2018

Derakhshankhah & Jafari, Biomedicine & Pharmacotherapy, 2018

View as image

Most cancer drugs face the same fundamental problem: getting inside the cell. The plasma membrane is a selective barrier that excludes large molecules, charged compounds, and many small-molecule therapeutics. Chemotherapy drugs like doxorubicin can cross membranes through passive diffusion, but their distribution is nonspecific, which is why they poison healthy cells alongside cancerous ones. Cell-penetrating peptides (CPPs) offer a different approach: short peptide sequences, typically 5 to 30 amino acids, that cross membranes efficiently and can carry therapeutic cargo with them. For the foundational story of the most studied CPP, see our guide to the TAT peptide.

The field began in 1988 when two independent groups discovered that the HIV-1 TAT protein could enter cells by crossing the plasma membrane directly. A decade later, researchers showed that short fragments of TAT retained this ability, and that fusing cargo molecules to these fragments allowed intracellular delivery of proteins, nucleic acids, and drugs that could not enter cells on their own. Since then, dozens of CPP families have been characterized, from the insect-derived penetratin to polyarginine sequences to entirely synthetic designs optimized by computational approaches. The question is no longer whether CPPs can deliver drugs into cells. They can. The question is whether they can do so selectively enough for clinical use in cancer.

How Cell-Penetrating Peptides Cross Membranes

The mechanism by which CPPs enter cells has been debated for over two decades. The current consensus recognizes three primary uptake routes, with the dominant pathway depending on peptide concentration, cargo size, and cell type.

Direct penetration occurs at high CPP concentrations. The positively charged peptide interacts with negatively charged phospholipid head groups in the membrane, causing local destabilization that allows the peptide (and its cargo) to translocate directly into the cytoplasm. This is the fastest route and bypasses the endosomal system entirely, meaning cargo arrives in the cytoplasm without risk of degradation in lysosomes.^[1]

Endocytosis is the more common route at physiological CPP concentrations. The peptide binds the membrane surface and is internalized via macropinocytosis, clathrin-mediated endocytosis, or caveolae-dependent pathways. The critical limitation here is endosomal escape: after internalization, the peptide-cargo complex is trapped inside endosomes that acidify and eventually fuse with lysosomes, degrading the cargo. A 2019 study noted that achieving efficient endosomal escape remains the single biggest challenge in CPP-mediated drug delivery.^[2]

Transient pore formation is a third mechanism observed with certain amphipathic CPPs. These peptides insert into the membrane and create short-lived pores through which cargo can pass. The pores reseal after the peptide dissociates, leaving the membrane intact. A 2023 classification of CPP uptake mechanisms noted that the boundaries between these three routes are not rigid: a single CPP can use different mechanisms depending on concentration, temperature, and membrane composition.^[3]

The Selectivity Problem

The most important limitation of first-generation CPPs for cancer therapy is that they are not selective. TAT, penetratin, and other classical CPPs enter all cells, not just cancer cells. This means a CPP-drug conjugate injected intravenously would deliver its toxic payload to healthy tissue as efficiently as to tumor tissue, defeating much of the purpose.

A 2019 review characterized this as the central paradox of CPP-based drug delivery: the same properties that make CPPs excellent at membrane translocation (positive charge, amphipathicity) make them promiscuous in their target selection.^[4] Three strategies have been developed to address this.

Tumor-activated CPPs are engineered to remain inactive in circulation and activate only at the tumor site. One approach uses pH-sensitive masking groups that shield the CPP's positive charges at normal blood pH (7.4) but fall away in the acidic tumor microenvironment (pH 6.5-6.8). A 2021 study demonstrated tumor-activated CPPs that showed dramatically increased uptake in tumor tissue compared to normal tissue in mouse models, with the activation triggered by matrix metalloproteinases or low pH characteristic of solid tumors.^[5] For an in-depth look at this approach, see our article on tumor-activated cell-penetrating peptides.

Receptor-targeting conjugation pairs a CPP with a tumor-targeting ligand (such as an RGD peptide that binds integrins overexpressed on tumor vasculature). The targeting ligand concentrates the conjugate at the tumor, and the CPP handles membrane translocation once there. This leverages the strengths of both components: specificity from the targeting peptide, penetration from the CPP.

Nanoparticle decoration uses CPPs as surface ligands on drug-loaded nanoparticles. A 2021 study showed that TAT-functionalized nanoparticles significantly enhanced intracellular delivery of doxorubicin to cancer cells in vitro, with the CPP coating improving cellular uptake compared to unmodified nanoparticles.^[6] The nanoparticle can include additional targeting elements and can exploit the enhanced permeability and retention (EPR) effect to accumulate passively in tumors before the CPP drives cell entry. For more on these conjugation strategies, see CPP-cargo conjugates.

What CPPs Can Deliver

The versatility of CPPs as delivery vehicles is one of their most compelling features. Unlike antibody-drug conjugates (which require covalent attachment to a large protein), CPPs can be linked to diverse cargo types through straightforward chemical conjugation or even noncovalent complexation.

Small-molecule chemotherapy drugs were the earliest CPP cargoes. Doxorubicin, paclitaxel, methotrexate, and cisplatin have all been delivered via CPP conjugates, with the general finding that CPP attachment increases intracellular drug concentration in cancer cells while, in some nanoparticle configurations, reducing systemic distribution to dose-limiting organs like the heart. A 2025 study demonstrated CPP-functionalized small molecule delivery with improved tumor penetration and reduced off-target effects.^[9]

Nucleic acids represent a particularly valuable cargo class because RNA and DNA cannot cross cell membranes unaided. CPPs have been used to deliver siRNA (for gene silencing), antisense oligonucleotides, plasmid DNA, and CRISPR components into cancer cells. The positively charged CPPs naturally complex with negatively charged nucleic acids, forming nanoparticles that protect the nucleic acid from degradation and facilitate cellular uptake.

Proteins and peptide therapeutics that have intracellular targets but cannot enter cells independently can be ferried across the membrane by CPP fusion. This includes pro-apoptotic peptides, tumor suppressor protein fragments, and antibody fragments targeting intracellular oncoproteins. A 2023 review highlighted that CPP-mediated protein delivery has expanded the druggable proteome by making previously inaccessible intracellular targets reachable.^[7]

Immunotherapy agents are the newest frontier. A 2025 review of CPP applications in cancer immunotherapy described how CPPs are being used to deliver immune checkpoint modulators, cancer vaccine antigens, and cytokine payloads directly into tumor cells or antigen-presenting cells, potentially boosting anti-tumor immune responses while limiting systemic immune activation.^[8] This is relevant to the broader landscape of anticancer peptides and peptide-drug conjugates.

Next-Generation CPP Design

The limitations of first-generation cationic CPPs (poor selectivity, endosomal trapping, potential toxicity at high doses) have driven the development of improved designs. Several approaches show promise.

Amphipathic CPPs contain both hydrophobic and hydrophilic domains, allowing them to interact with membranes in ways that pure cationic peptides cannot. A 2025 study on amphipathic proline-rich CPPs demonstrated that these structures achieved efficient cell penetration with lower cytotoxicity than classical cationic CPPs, suggesting a path toward therapeutically viable peptide delivery vehicles.^[10]

Cyclic CPPs constrain the peptide backbone into a ring structure, improving proteolytic stability and, in some cases, enhancing membrane permeability. The rigidity of the cyclic scaffold can also improve target selectivity by limiting conformational flexibility that might otherwise allow off-target interactions.

pH-responsive CPPs incorporate histidine residues or other ionizable groups that change the peptide's charge state at acidic pH. These CPPs show minimal membrane activity at physiological pH but become highly membrane-active in the acidic tumor microenvironment (pH 6.2-6.8) or within acidic endosomes (pH 5.0-6.0), providing both tumor selectivity and endosomal escape in a single design element.

Computationally designed CPPs use machine learning and molecular dynamics simulations to predict optimal sequences for membrane penetration, cargo binding, and tumor selectivity. This approach has accelerated the design cycle from trial-and-error synthesis to rational engineering, with some groups reporting computationally designed CPPs that outperform natural sequences in penetration efficiency. AlphaFold and related structure-prediction tools have further enabled rational CPP design by predicting how peptide sequences will fold in different membrane environments, allowing researchers to screen thousands of candidate sequences in silico before synthesizing the most promising ones.

Where the Clinical Pipeline Stands

Despite three decades of research, no CPP-based cancer therapy has received regulatory approval. Several CPP-drug conjugates have entered early-phase clinical trials, primarily for solid tumors that are poorly accessible to conventional chemotherapy. The gap between preclinical promise and clinical reality reflects both scientific and commercial challenges.

The scientific bottleneck centers on pharmacokinetics and biodistribution. CPPs must survive in circulation long enough to reach tumors, resist proteolytic degradation by blood and tissue enzymes, and not accumulate in dose-limiting organs like the kidneys and liver. Short peptides are cleared rapidly by renal filtration, giving a narrow window for tumor accumulation. PEGylation (attaching polyethylene glycol chains) and nanoparticle encapsulation extend circulation time but add manufacturing complexity.

Manufacturing represents a separate barrier. CPP-drug conjugates require quality-controlled peptide synthesis at pharmaceutical scale, which remains significantly more expensive than small-molecule drug production. Each conjugation chemistry must be validated for stability, purity, and batch-to-batch consistency. Immunogenicity is a concern for some CPP sequences, particularly longer ones or those derived from non-human proteins like HIV TAT.

The most clinically advanced programs use tumor-activated CPPs or CPP-decorated nanoparticles rather than simple CPP-drug conjugates, reflecting the field's recognition that selectivity is non-negotiable for clinical utility. The concept of selectively enabling CPP activity at the tumor site has shifted from an optional improvement to a core design requirement. The parallel development of tumor-targeting peptide libraries is accelerating this work, as tumor-homing sequences can be combined with CPP sequences to create dual-function delivery vehicles.

The Bottom Line

Cell-penetrating peptides solve a fundamental problem in cancer drug delivery: getting therapeutic molecules across the cell membrane and into the cytoplasm. Three decades of research have produced dozens of CPP families, characterized their uptake mechanisms (direct penetration, endocytosis, pore formation), and demonstrated delivery of chemotherapy drugs, nucleic acids, proteins, and immunotherapy agents in preclinical models. The central challenge remains selectivity: CPPs enter all cells, not just cancer cells, which has driven the development of tumor-activated and receptor-targeted designs. Several CPP-based therapies are in early clinical trials, but none have yet reached regulatory approval. The field's trajectory points toward increasingly sophisticated, conditionally active designs that combine CPP penetration power with tumor-specific targeting.

Frequently Asked Questions

What are cell-penetrating peptides used for in cancer treatment?

Cell-penetrating peptides are used as delivery vehicles to transport cancer drugs, siRNA, proteins, and immunotherapy agents across cell membranes that would otherwise block their entry. By conjugating a therapeutic cargo to a CPP, researchers can increase intracellular drug concentrations in cancer cells, potentially improving efficacy and reducing the doses needed for treatment.

How do cell-penetrating peptides get inside cells?

CPPs cross cell membranes through three main routes: direct penetration (at high concentrations, the positively charged peptide disrupts the lipid bilayer and passes through), endocytosis (the cell engulfs the peptide in vesicles), and transient pore formation (the peptide creates temporary openings in the membrane). The dominant route depends on peptide concentration, cargo size, and cell type.

Can cell-penetrating peptides target cancer cells specifically?

First-generation CPPs like TAT and penetratin enter all cell types indiscriminately. To achieve cancer selectivity, researchers have developed tumor-activated CPPs that only become active in the acidic tumor environment or when cleaved by tumor-associated enzymes. Receptor-targeting conjugation and nanoparticle-based approaches also improve tumor specificity.

What is the TAT peptide and where does it come from?

TAT is a cell-penetrating peptide derived from the HIV-1 Trans-Activator of Transcription protein. Discovered in the late 1980s, the short peptide sequence RKKRRQRRR retains the ability to cross cell membranes and has become the most widely studied CPP in cancer research. Despite its viral origin, the peptide itself has no HIV-related effects when used as a delivery vehicle.

Are any cell-penetrating peptide cancer treatments FDA approved?

No CPP-based cancer therapy has received FDA approval as of 2026. Several CPP-drug conjugates and CPP-decorated nanoparticles are in Phase I/II clinical trials for solid tumors. The main barriers to approval are manufacturing cost, pharmacokinetic complexity, and achieving sufficient tumor selectivity to demonstrate a favorable risk-benefit profile.

What is the difference between CPPs and antibody-drug conjugates?

Both CPPs and antibody-drug conjugates (ADCs) deliver drugs to cancer cells, but they work differently. ADCs use antibodies to target specific surface receptors on cancer cells and release drugs after internalization. CPPs cross membranes directly and can deliver cargo to any cell type. ADCs have better tumor selectivity but are limited to cancers expressing the target receptor. CPPs are more versatile in cargo type but require additional engineering for selectivity.